CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Dubai, United Arab Emirates, 27 – 31 October 2019
An exploratory analysis from the Phase 3b FOCUS study of fremanezumab in episodic and chronic migraine has shown comparable efficacy in patients in the Czech Republic, Finland and the USA. Changes from baseline in average migraine headache days over 12 weeks were significantly greater with monthly and quarterly fremanezumab than placebo in all three countries …
Read more »The International Headache Society Global Patient Advocacy Coalition (IHS-GPAC) is developing a series of strategies and resources to raise awareness and support patients with migraine in the workplace. This follows a successful collaboration with the leading information and communication technology company, Fujitsu, in Japan, which demonstrated the significant impact of migraine on productivity. “The workplace …
Read more »Nearly three quarters of participants in a Phase 3 trial of galcanezumab in chronic cluster headache were using one preventive at baseline and nearly a quarter were using two, with verapamil the most common choice, according to a new evaluation of the study.1 The most commonly used acute treatments were oxygen and subcutaneous sumatriptan. Under …
Read more »Migraine is a substantial clinical and economic burden in Eurasian countries, though use of preventive migraine medication is low, according to a systematic literature review reported for China, Israel, Russia, South Korea, and Turkey. Analysis of papers published from 2008-2018 showed that migraine prevalence was reported as 7.9–9.7% in China, 17.8% in Israel, 17.0% in …
Read more »Raised serum CGRP levels may indicate a migrainous aetiology for recurrent painful ophthalmoplegic neuropathy (RPON)/ophthalmoplegic migraine (OM) and may prove useful as a diagnostic biomarker. RPON/OM is a rare neurologic disorder with headache characteristics, temporal profile and response to treatment similar to migraine, with nerve enhancement on imaging pointing to cranial nerve pathology. In a …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
